TABLE 1.
Comparison of neoadjuvant chemotherapy (NAC) patients versus non-NAC patients
| Variable | Adjuvant/no chemotherapy (N = 124) | NAC (N = 81) | P value |
|---|---|---|---|
| Age (years) | 54.3 | 50.6 | 0.02 |
| BMI (kg/m2) | 29.7 | 28.8 | 0.36 |
| Race | 0.78 | ||
| White | 78% (97) | 73% (59) | |
| Black | 10% (12) | 11% (9) | |
| Hispanic | 10% (13) | 15% (12) | |
| Other | 2% (3) | 1% (1) | |
| Tumor size (T)a | <0.01 | ||
| T1 | 57% (71) | 10% (8) | |
| T2 | 38% (47) | 35% (28) | |
| T3 | 3% (4) | 19% (15) | |
| T4 | 2% (2) | 37% (30) | |
| Stage (AJCC) | <0.01 | ||
| Stage 1 | 44% (54) | 1% (1) | |
| Stage 2 | 44% (55) | 37% (30) | |
| Stage 3 | 12% (15) | 62% (50) | |
| Premenopausal | 28% (35) | 39% (31) | 0.10 |
| LN statusb | 41% (51) | 60% (48) | 0.008 |
| ER | 79% (98) | 57% (46) | 0.001 |
| PR | 65% (80) | 42% (34) | 0.001 |
| HER2 gene amplification | 6% (8) | 33% (27) | <0.001 |
| Intrinsic subtypesc | |||
| TNBC subtype | 18% (22) | 22% (18) | 0.43 |
| Luminal A subtype | 76% (94) | 46% (37) | <0.001 |
| Luminal B subtype | 5% (6) | 14% (11) | 0.03 |
| HER2 subtype | 2% (2) | 19% (15) | <0.001 |
| LVI | 28% (34) | 30% (20) | 0.77 |
| High tumor grade | 35% (43) | 66% (53) | <0.001 |
| pCR | NA | 30% (24) | NA |
| DTCs | 32% (39) | 25% (20) | 0.29 |
AJCC AJCC Cancer Staging Manual,16 LVI presence of lymphovascular invasion, NAC neoadjuvant chemotherapy, DTCs disseminated tumor cells in bone marrow, pCR pathologic complete response,10 BMI body mass index
a
Tumor size: T1, ≤2 cm; T2, >2 cm and ≤5 cm; T3, >5 cm; T4, any tumor size extending to overlying skin or chest wall
b
LN status: presence of axillary lymph node metastases
c
TNBC: triple negative breast cancer (ER–, PR–, HER2–); luminal A subtype (ER+, and/or PR+, HER2–); luminal B subtype (ER+, and/or PR+, HER2+); HER2 subtype (ER–, PR–, HER2+)